ClearPoint Neuro (NASDAQ:CLPT) Upgraded by Wall Street Zen to "Hold" Rating

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Separately, Stifel Nicolaus increased their price target on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st.

ClearPoint Neuro Trading Down 4.5%

CLPT opened at $11.54 on Friday. The firm has a market capitalization of $322.99 million, a PE ratio of -16.72 and a beta of 0.93. ClearPoint Neuro has a twelve month low of $5.11 and a twelve month high of $19.22. The firm's 50-day moving average price is $12.81 and its 200 day moving average price is $14.30.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The company had revenue of $8.49 million during the quarter, compared to analysts' expectations of $8.21 million. As a group, analysts predict that ClearPoint Neuro will post -0.66 earnings per share for the current fiscal year.

Insider Buying and Selling at ClearPoint Neuro

In other ClearPoint Neuro news, CEO Joseph Burnett sold 21,247 shares of the business's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $13.29, for a total value of $282,372.63. Following the sale, the chief executive officer now directly owns 243,522 shares in the company, valued at approximately $3,236,407.38. The trade was a 8.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Timothy T. Richards sold 10,000 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total transaction of $132,800.00. Following the completion of the sale, the director now owns 77,381 shares in the company, valued at approximately $1,027,619.68. This trade represents a 11.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.97% of the stock is owned by insiders.

Institutional Trading of ClearPoint Neuro

Several institutional investors and hedge funds have recently bought and sold shares of the stock. AlphaQuest LLC acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at about $80,000. Deutsche Bank AG acquired a new position in shares of ClearPoint Neuro in the 1st quarter valued at about $63,000. Tower Research Capital LLC TRC acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at about $93,000. State of Wyoming acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at about $145,000. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of ClearPoint Neuro in the 4th quarter valued at about $155,000. Institutional investors and hedge funds own 30.08% of the company's stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.